OTCPK:SNBP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Sun BioPharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SNBP has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-7.7%

SNBP

0.5%

US Biotechs

1.7%

US Market


1 Year Return

112.4%

SNBP

23.3%

US Biotechs

8.5%

US Market

Return vs Industry: SNBP exceeded the US Biotechs industry which returned 23.3% over the past year.

Return vs Market: SNBP exceeded the US Market which returned 8.5% over the past year.


Shareholder returns

SNBPIndustryMarket
7 Day-7.7%0.5%1.7%
30 Day-8.6%7.7%9.5%
90 Dayn/a9.0%0.1%
1 Year112.4%112.4%24.5%23.3%11.0%8.5%
3 Year-69.8%-69.8%34.3%29.8%32.2%23.5%
5 Yearn/a-3.7%-9.5%58.6%40.8%

Price Volatility Vs. Market

How volatile is Sun BioPharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Sun BioPharma undervalued compared to its fair value and its price relative to the market?

43.96x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SNBP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SNBP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SNBP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SNBP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SNBP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SNBP is overvalued based on its PB Ratio (44x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Sun BioPharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

30.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sun BioPharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Sun BioPharma performed over the past 5 years?

-5.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SNBP is currently unprofitable.

Growing Profit Margin: SNBP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SNBP is unprofitable, and losses have increased over the past 5 years at a rate of -5.8% per year.

Accelerating Growth: Unable to compare SNBP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: SNBP has a negative Return on Equity (-886.33%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sun BioPharma's financial position?


Financial Position Analysis

Short Term Liabilities: SNBP's short term assets ($2.1M) exceed its short term liabilities ($1.4M).

Long Term Liabilities: SNBP has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: SNBP's debt to equity ratio (115.1%) is considered high.

Reducing Debt: SNBP had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SNBP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SNBP has less than a year of cash runway if free cash flow continues to grow at historical rates of 8% each year.


Next Steps

Dividend

What is Sun BioPharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SNBP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SNBP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SNBP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SNBP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SNBP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Michael Cullen (73yo)

1.58yrs

Tenure

US$659,821

Compensation

Dr. Michael T. Cullen, Jr., M.D., M.B.A., is President and Chief Executive Officer at Sun BioPharma, Inc. since November 2018. He co-founded Sun BioPharma, Inc. in November 2011 and served as its President ...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD659.82K) is about average for companies of similar size in the US market ($USD591.64K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Cullen
Co-Founder1.58yrsUS$659.82k6.07% $1.9m
Susan Horvath
VP of Finance2.17yrsUS$401.44k0.13% $40.9k
Thomas Neenan
Co-Founder & Chief Scientific Officerno datano datano data
Tammy Groene
Vice President of Operationsno datano datano data
Suzanne Gagnon
Chief Medical Officer & Directorno datano data0.77% $245.5k
Anthony Kiorpes
Toxicology Consultantno datano datano data
Kristen Flaharty
Pharmacology Consultant2.42yrsno datano data

2.3yrs

Average Tenure

62yo

Average Age

Experienced Management: SNBP's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Cullen
Co-Founder1.58yrsUS$659.82k6.07% $1.9m
Suzanne Gagnon
Chief Medical Officer & Directorno datano data0.77% $245.5k
Jeffrey Mathiesen
Independent Director4.75yrsUS$62.40k0.045% $14.4k
Manuel Hidalgo
Member of Scientific Advisory Boardno datano datano data
Arthur Fratamico
Independent Director0.50yrUS$74.99kno data
Donald Schemel
Independent Director4.75yrsUS$62.40k5.61% $1.8m
Paul Schaffer
Independent Director4.75yrsUS$62.40k2.34% $744.4k
Ashok Saluja
Member of Scientific Advisory Boardno datano datano data
Steven Pandol
Member of Scientific Advisory Boardno datano datano data
Raymond Bergeron
Member of Scientific Advisory Boardno datano datano data

4.8yrs

Average Tenure

62yo

Average Age

Experienced Board: SNBP's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.8%.


Top Shareholders

Company Information

Sun BioPharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sun BioPharma, Inc.
  • Ticker: SNBP
  • Exchange: OTCPK
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$31.830m
  • Shares outstanding: 6.63m
  • Website: https://www.sunbiopharma.com

Number of Employees


Location

  • Sun BioPharma, Inc.
  • 712 Vista Boulevard
  • Suite 305
  • Waconia
  • Minnesota
  • 55387
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SNBPOTCPK (Pink Sheets LLC)YesNew Common StockUSUSDSep 2015

Biography

Sun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with pancreatic cancer. The company has scientific collaborations with pancreatic disease experts Cedars Sinai Medical Center in Los Angeles, the University of Miami; the University of Florida; the Austin Health Cancer Trials Centre in Melbourne, Australia; the Ashford Cancer Centre in Adelaide, Australia; and the Blacktown Cancer and Haematology Centre in Sydney, Australia. Sun BioPharma, Inc. was founded in 2011 and is based in Waconia, Minnesota. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/03 04:51
End of Day Share Price2020/06/02 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.